Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

Abstract Background Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104–183 per 100,000 person-years. After a VTE episode, the two-year recurrence rate is about 17%. Consequently, effective and safe anticoagulation is par...

Full description

Bibliographic Details
Main Authors: Alexander T. Cohen, Cihan Ay, Philippe Hainaut, Hervé Décousus, Ulrich Hoffmann, Sean Gaine, Michiel Coppens, Pedro Marques da Silva, David Jiménez, Beatrice Amann-Vesti, Bernd Brüggenjürgen, Pierre Levy, Julio Lopez Bastida, Eric Vicaut, Petra Laeis, Eva-Maria Fronk, Wolfgang Zierhut, Thomas Malzer, Peter Bramlage, Giancarlo Agnelli, on behalf of the ETNA-VTE-Europe investigators
Format: Article
Language:English
Published: BMC 2018-05-01
Series:Thrombosis Journal
Subjects:
Venous thromboembolism (VTE)
Edoxaban
Direct oral anticoagulant (DOAC/NOAC)
Anticoagulation
Registry
Online Access:http://link.springer.com/article/10.1186/s12959-018-0163-7

Similar Items

Similar Items